echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Study of Nervous System > Eli Lilly and MiNA develop a new drug based on the saRNA platform, Bojian and Ca...

    Eli Lilly and MiNA develop a new drug based on the saRNA platform, Bojian and Ca...

    • Last Update: 2021-05-23
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    CompileKe Ke

    On May 11, Eli Lilly and MiNA Therapeutics, an RNA activation therapy company, announced a global research collaboration to develop new drug candidates using MiNA's proprietary small molecule activated RNA (saRNA) technology platform.


    According to the terms of the agreement, MiNA will use its saRNA platform to research five targets selected by Eli Lilly, aimed at addressing diseases in Lilly's key therapeutic areas.


    At the same time, Biogen and Capsigen also announced that they have reached a strategic research cooperation to design a new adeno-associated virus (AAV) capsid, which may provide transformative gene therapy to solve the problem.


    As part of the collaboration, Capsigen’s patented TRADE™ platform and related technologies will be used to create and identify new AAV capsids to meet disease-specific transduction profiles.


    Under the terms of the agreement, Capsigen will apply its vector engineering methods to develop new capsids to meet highly customized disease-specific transduction profiles.


    Reference source:

    Reference source:

    1.


    1.


    2.
    Biogen and Capsigen Announce Collaboration to Discover and Develop Novel AAV Capsids for Targeted CNS and Neuromuscular Disorders
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.